Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $70,223.34 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 6,198 shares of the company’s stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $382,092.92. This trade represents a 15.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Houte Hans Van also recently made the following trade(s):

• On Wednesday, April 30th, Houte Hans Van sold 2,438 shares of Nurix Therapeutics stock. The shares were sold at an average price of $11.50, for a total transaction of $28,037.00.
• On Monday, March 3rd, Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock. The shares were sold at an average price of $14.49, for a total transaction of $84,404.25.

Nurix Therapeutics Trading Up 1.0 %

Shares of NASDAQ:NRIX opened at $11.27 on Friday. The firm has a 50 day simple moving average of $12.03 and a 200-day simple moving average of $17.99. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56. The company has a market capitalization of $859.18 million, a PE ratio of -3.90 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million during the quarter, compared to analysts’ expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the previous year, the company earned ($0.76) earnings per share. As a group, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its position in shares of Nurix Therapeutics by 2.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company’s stock worth $585,000 after acquiring an additional 642 shares during the last quarter. Corebridge Financial Inc. grew its position in Nurix Therapeutics by 2.3% during the 4th quarter. Corebridge Financial Inc. now owns 34,907 shares of the company’s stock worth $658,000 after purchasing an additional 770 shares during the last quarter. Kennedy Capital Management LLC increased its stake in Nurix Therapeutics by 0.7% in the fourth quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company’s stock valued at $2,159,000 after purchasing an additional 785 shares during the period. US Bancorp DE raised its holdings in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after buying an additional 842 shares during the last quarter. Finally, Summit Investment Advisors Inc. boosted its stake in shares of Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock worth $138,000 after buying an additional 877 shares during the period.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on NRIX. Needham & Company LLC reaffirmed a “buy” rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday. Wells Fargo & Company cut their price objective on Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, April 9th. Leerink Partnrs upgraded shares of Nurix Therapeutics to a “hold” rating in a research note on Monday, March 17th. Royal Bank of Canada raised their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Finally, Morgan Stanley increased their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.44.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.